Deltex Medical Share Discussion Threads

[february 30th] 18/6/2016 01:13

I think he just transferred some shares from one account into another.

[djgrantb] 17/6/2016 16:14

Yep someone was increasing their stake - Ewan the CEO lol

[djgrantb] 15/6/2016 08:52

Is someone building a stake buy/sell trades suggests so?

[ramnik007] 12/6/2016 07:21

Dr Liam Brennan representing The Royal College of Anaesthetists (RCoA), which carried out the research, warned that patients and the smooth running of hospitals would be hit if the existing shortfall in numbers was allowed to increase.

Brennan goes on to say “These shortages mean that doctors who are already overstretched are having to work even harder to maintain services, particularly for urgent and emergency care for patients. They are going the extra mile on a daily basis to fill these gaps."

Perhaps Brennan should comment on why his mates fail to adopt innovative medical tech that would save both hours worked in surgery and improve quality of care.

Full article :

[bigt20] 10/6/2016 11:39

1500 covers the US sales force but there are some other costs.

[fozdad] 09/6/2016 16:41

9d, not entirely sure what you mean but I don't think any extra Deltex staff are required to service the new accounts in today's RNS. All the infrastructure is in place across the US other than for a couple of regions.

They have previously said that when the US are producing a demand of 1500 probes per month, they will be covering local costs and contributing to central costs.

Today's news means we are very close to this milestone (if not through it).

[yump] 09/6/2016 16:37

That's a good question as there is presumably a set of costs associated with the US and the only clue at the moment is they gave the number of US accounts needed to cover costs - somewhere - I think.

I did try to look at the probe revenue from the very early US accounts to see if I could work out how long each new one might take to get up to or above 50 probes a month.

Then assume some sort of average sales and sales growth across all the US accounts, but I gave up on the basis that at some point in the next year, we should get the probe data from a much larger number of US accounts.

At which point the calcs. and extrapolation for break-even or profit will be a lot easier and way more accurate.

The company might spell it out at some point as well.

[9degrees] 09/6/2016 14:29

Do these new accounts cover the cost and more of the sales person in the US?

[supernumerary] 09/6/2016 11:39

arf - 'However, what matters to me is that we now have 24 platform accounts in America, and we'll reach 30 fairly soon.' Yes, which will set them up nicely for a little fund raise, 'to fund further expansion'!

[arf dysg] 09/6/2016 11:27

If a British company whose accounting year ends on the 31st of December, announces to its British shareholders that something will happen by "mid year", I take that to be the end of June.

However, what matters to me is that we now have 24 platform accounts in America, and we'll reach 30 fairly soon.

[the count] 09/6/2016 09:36

--->AMT

I too have always understood it to be 'By US Labor Day', so as SIDAM says, there is no current slippage yet on their current promise.

A step in the right direction certainly.

THE COUNT!

[amt] 09/6/2016 08:22

Well if mid year is September, I stand corrected and looks to be very much on target.

[sidam] 09/6/2016 08:19

Amt
I think you will find that for a couple of years mid year has been said to be before Labor Day so there are 3 months not weeks. However that is semantic and 30 is only a round number.

I think this stock will go much higher given time and is now one of my largest holdings.

[fozdad] 09/6/2016 08:03

Exactly so amt, I note that the 30 platform target has slipped from mid year, to first week in September (in the recent presentation) to "in the coming months".

But we also had confirmation that US probe revenues are up over 50% in the first 5 months, we'll have to see how this balances out with the continuing decline of UK revenues and whether we become cash generative before cash runs out.

[amt] 09/6/2016 07:57

So they need 6 more in 3 weeks to meet the target of 30 by mid year. Looks like they over promised but that's why the share price is so low. Moving steadily in the right direction and so with patience should get big rewards.

[trotterstrading] 04/6/2016 21:29

Oak, good post. I agree with your sentiments. DEMG is beaten up and unloved, but i honestly think they've now turned a corner, once this becomes more tangible I think the rebound in share price will be be dramatic. It's also a big takeover target in 2017 IMO, which adds to the appeal.

[the oak tree] 03/6/2016 18:36

After a very long time watchng this, I've finally decided to buy a few today.

I have to say I hate the £££; figures and each time I've looked at it in the past it just looks way too expensive. Market cap is double the turnover and still loss making after so many false dawns.

So why now? Well I feel they tried the NHS and have paid the price and are now making headway abroad. The spainish trail gives me hope the product is genuine and sales will roll in. I like that insurance companies may require it as it could keep their costs down.

Normaly I like value stocks , but while still expensive , I've often seen unloved blue sky story situations like this rebound strongly when mgt push through problems.

I can only think most that would sell have done so already, that gives a good upside.

[arf dysg] 03/6/2016 12:33

Thanks TT.

[bigt20] 02/6/2016 22:12

Thanks Trotters.

[trotterstrading] 02/6/2016 20:44

Very interesting:Deltex Medical Group plc (LON:DEMG) Chief Executive Officer Ewan Phillips caught up with DirectorsTalk for an exclusive interview to discuss the launch of TruFlow, the improvements for physicians, encouraging sales and reducing the number of dedicated trainers Q1: Now Deltex Medical Group have just announced the launch of TruFlow, can you give us a bit of background on how you came to develop the new probe?A1: Yes, we've got a technology, oesophageal Doppler, which is a very very high end technology, the sort of things we can do the alternatives to get there are very expensive, tens of thousands of pounds, we really stripped that down to get right into the central circulation and get a very good view point of what's going on. The precise engineering background, that's had a very small focal beam which means you have to line up the small beam with a very small window to do that, which is well worth it when you get there but it does mean that there's quite a knack to getting there. So we've been looking for a long time to find ways of having a larger focal beam so it's easier to get the right focus and holds it focus better, particularly when moving a patient around. That's why we've been doing that, the step we've got is to re-orientate the crystals we use which just changes the way the ultrasound flows through the body which means you've got a much bigger focal point and a wider beam and the results have been great. Q2: I think you've touched on it there but what are the improvements that physicians can expect to see when they're using them?A2: Well it means that the new user in particular will find it much easier to get the knack of focussing these things, experienced users for someone who can put it in and get a signal in a matter of seconds there isn't much better you can do than that. The sort of feedback we've had is that the performance relative to the old one is 'outstanding', 'exceptional', 'fantastic' which are words, frankly in the medical device business, you don't get very often from your customers so excellent from that. The real thing that they like is that once you're in position there, you hold that position and are able to focus much better. These days with types of surgery, they'll put patients facedown, lie them down on the bed and then tip the bed have them facedown, head down, now that position if you have to re-focus the probe it's awkward, physically awkward for the doctor, so having something that holds the focus better just makes it that much easier to use which always just removes the barrier to getting on and doing it. Q3: Do you think that the release of the new probe will encourage sales?A3: Yes it will, Deltex Medical Group have got two different areas there. We are expanding in pretty much all of our export markets and particularly focussing on the States at the moment, there this isn't an improved probe this is just the probe now and it's an easy to use technology that you can learn quickly so that's a real positive. The UK, which is in a more difficult time with all the NHS's problems at the moment and people are being sort of bullied by procurement to spend as little as possible, is anything we do that keeps it fresh and new will help the whole sales process on top of all the evidence and reassuring people that the benefit of using this is huge and actually the downside of not using these probes, to see what's going on in the circulation, is bad for patients and it wastes a lot of money for the complications you fail to avoid. Q4: Will the increased use of the probe mean the number of dedicated trainers can decrease as less training is needed to use the monitor and the associated probe?A4: Yes, very much so. Historically, the suggestion was it takes about 10 to 12 probing sessions/patients before you could expect a user to be independent. Now we've been working on that over the last 2 or 3 years, we're bringing in learning modules which has cut the learning curve, we allow people to train with a simulator which is a mannequin where you can get the knack and do all of those sorts of things like that, now the probe just being easier I suspect it's probably down to getting nearer to the 2 or 3 patients before you've got the knack. Doesn't mean we don't have to educate people into what the images we generate, what they mean and what they're telling them about the circulation but that's a much higher level education rather than the sort of manual process of getting the knack. So yes, it'll be less effort from Deltex Medical Group but it'll also be higher value effort in terms of really driving forward better healthcare.

[bigt20] 02/6/2016 20:11

Well at least this study is multi centred and funded by the Spanish government so that should shut up some (some on here will know who this refers to)!

Those of us who have been around for a while have been waiting for some action on the Spanish front, so the big question is when do we see some sort of uplift in the sales to Spain?

Well I dont expect much this year given the comments in the 2015 Annual Report.

[shrewdmole] 02/6/2016 15:30

Tt

The 250k looks like a rollover but someone's confident to be doing that.

I'm remote so signals not the best what was the nice review about?

Shrewdie

[djgrantb] 02/6/2016 15:20

MMs must be short of the stock 4.95 on the ask.

[djgrantb] 02/6/2016 14:36

Spanish study results are outstanding, nice buying volume today, onwards and upwards, need to push through 5p resistance. imho